BACKGROUND: The additional burden of HCV infection in HIV-HCV-coinfected individuals may have some consequences on adherence to HAART. Few studies have explored the pattern of correlates of non-adherence to HAART while simultaneously considering the impact of HCV treatment and depressive symptoms on adherence to HAART. We used longitudinal data to assess factors associated with non-adherence to HAART. METHODS: The French national prospective cohort ANRS-CO13-HEPAVIH is a multicentrer cohort, which recruited 1,175 HIV-HCV-coinfected patients in 17 hospital outpatient units delivering HIV and HCV care in France between October 2006 and June 2008. For this analysis, we selected participants on HAART with self-reported data for adherence to HAART (n=727 patients, 1,190 visits). Data were collected using self-administered questionnaires and medical records. A mixed logistic regression model based on an exchangeable correlation matrix was used to identify factors associated with non-adherence to HAART. RESULTS: Patients reported non-adherence to HAART in 808 (68%) of the 1,190 visits. Four variables remained associated with non-adherence to HAART after multivariate analysis: hazardous alcohol consumption, cocaine use and depressive symptoms, regardless of whether treatment for depression was being received. Finally, patients being treated for HCV infection were less likely to be non-adherent to HAART. CONCLUSIONS: Besides the problem of polydrug use, two other dimensions deserve special attention when considering adherence to HAART in HIV-HCV-coinfected patients. Access to HCV treatment should be encouraged as well adequate treatment for depression in this population to improve adherence and response to HAART.
BACKGROUND: The additional burden of HCV infection in HIV-HCV-coinfected individuals may have some consequences on adherence to HAART. Few studies have explored the pattern of correlates of non-adherence to HAART while simultaneously considering the impact of HCV treatment and depressive symptoms on adherence to HAART. We used longitudinal data to assess factors associated with non-adherence to HAART. METHODS: The French national prospective cohort ANRS-CO13-HEPAVIH is a multicentrer cohort, which recruited 1,175 HIV-HCV-coinfectedpatients in 17 hospital outpatient units delivering HIV and HCV care in France between October 2006 and June 2008. For this analysis, we selected participants on HAART with self-reported data for adherence to HAART (n=727 patients, 1,190 visits). Data were collected using self-administered questionnaires and medical records. A mixed logistic regression model based on an exchangeable correlation matrix was used to identify factors associated with non-adherence to HAART. RESULTS:Patients reported non-adherence to HAART in 808 (68%) of the 1,190 visits. Four variables remained associated with non-adherence to HAART after multivariate analysis: hazardous alcohol consumption, cocaine use and depressive symptoms, regardless of whether treatment for depression was being received. Finally, patients being treated for HCV infection were less likely to be non-adherent to HAART. CONCLUSIONS: Besides the problem of polydrug use, two other dimensions deserve special attention when considering adherence to HAART in HIV-HCV-coinfectedpatients. Access to HCV treatment should be encouraged as well adequate treatment for depression in this population to improve adherence and response to HAART.
Authors: Paula Braitstein; Amy Justice; David R Bangsberg; Benita Yip; Victoria Alfonso; Martin T Schechter; Robert S Hogg; Julio S G Montaner Journal: AIDS Date: 2006-02-14 Impact factor: 4.177
Authors: Thomas Kerr; Brandon D L Marshall; M-J Milloy; Ruth Zhang; Silvia Guillemi; Julio S G Montaner; Evan Wood Journal: Drug Alcohol Depend Date: 2012-01-14 Impact factor: 4.492
Authors: Lydia N Drumright; Holly Hagan; David L Thomas; Mary H Latka; Elizabeth T Golub; Richard S Garfein; John D Clapp; Jennifer V Campbell; Sebastian Bonner; Farzana Kapadia; Thelma King Thiel; Steffanie A Strathdee Journal: J Hepatol Date: 2010-11-24 Impact factor: 25.083
Authors: L Michel; V Villes; F Dabis; B Spire; M Winnock; M-A Loko; I Poizot-Martin; M A Valantin; P Bonnard; D Salmon-Céron; M P Carrieri Journal: J Viral Hepat Date: 2009-11-11 Impact factor: 3.728